Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell | Nature Medicine
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars | Biosimilars Law Bulletin
Novartis nabs much-needed new nod for slow-growing breast cancer drug Kisqali | Fierce Pharma
Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
PDF) Global regulatory challenges of CAR T-cell therapies: approval, pricing, and access
The Process of CAR-T Cell Therapy | Novartis
FDA staffers like Sandoz' biosimilarity data for copy of Amgen's Enbrel | Fierce Pharma
FDA Panel Votes Unanimously in Favor of First CAR-T Cancer Therapy | RAPS
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy | Nature Communications
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
Novartis receives first ever FDA approval for a CAR-T cell therapy
CAR T-Cell Therapy Hits Prime Time; Challenges Remain
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials - ScienceDirect
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials - ScienceDirect
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials - ScienceDirect
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Novartis CEO opens door to cancer patient demanding 'fair' CAR-T pricing | Fierce Pharma
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials
Racing toward a historic CAR-T approval, Novartis wins unanimous FDA panel backing | Fierce Pharma
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
